Table 3. Comparison of the cardioprotective efficacy of TAK-272 and aliskiren with respect to cardiac hypertrophy and plasma heart failure biomarker level.

Parameter	Group (n)
	WT	CSQ-tg
	Vehicle	Vehicle	TAK-272	Aliskiren
			300 mg/kg	300 mg/kg
	(4)	(8)	(11)	(12)
Body weight (g)	19.6 ± 0.6	15.8 ± 1.5##	19.1 ± 1.0**	16.6 ± 2.3
Left ventricle (mg)	67.4 ± 1.4	154.4 ± 15.8##	150.0 ± 9.2	150.2 ± 11.6
Right ventricle (mg)	14.5 ± 1.4	46.0 ± 6.8##	40.6 ± 5.3*	45.5 ± 3.0
Left atrium (mg)	2.1 ± 0.3	14.3 ± 3.8##	8.2 ± 3.0**	11.4 ± 2.2
Right atrium (mg)	2.9 ± 0.8	8.1 ± 1.8##	5.3 ± 0.8*	7.9 ± 2.2
Lung (mg)	120.5 ± 7.4	138.7 ± 15.0#	121.3 ± 10.1*	129.9 ± 13.6
NT-proBNP (ng/ml)	1.0 ± 0.1	8.5 ± 3.5##	4.5 ± 1.3*	7.7 ± 2.3

The body weights, cardiac tissue and lung weights, and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels of wild-type (WT) (n = 4) and calsequestrin transgenic (CSQ-tg) mice orally treated with vehicle (n = 8), TAK-272 (300 mg/kg, n = 11), or aliskiren (300 mg/kg, n = 12) are indicated. Data are expressed as the mean ± S.D. The number of deaths in each group during the study period was as follows: 0, 4, 1, and 0 in WT, vehicle, TAK-272, and aliskiren groups, respectively.

^#P < 0.05

^##P < 0.01 vs. WT, by Student's t-test or Aspin-Welch's t-test

*P < 0.05

**P < 0.01 vs. CSQ-tg + vehicle by Dunnett's test or Steel's test.